Skip to main content
KOMIPHARM INTERNATIONAL CO., LTD. logo

KOMIPHARM INTERNATIONAL CO., LTD. — Investor Relations & Filings

Ticker · 041960 ISIN · KR7041960006 KO Manufacturing
Open in API
Filings indexed 326 across all filing types
Latest filing 2020-05-14 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 041960

About KOMIPHARM INTERNATIONAL CO., LTD.

https://komipharm.co.kr/en/

Komipharm International Co., Ltd. is a biopharmaceutical company engaged in the development, manufacturing, and sale of products for both animal and human health. Its Animal Health Division provides a portfolio of veterinary vaccines, pharmaceuticals, and disinfectants. The company's Pharmaceutical Division is dedicated to the research and development of novel therapeutic agents, with key research areas including anticancer drugs and treatments for cancer-related pain and autoimmune diseases. Leveraging extensive experience, the company focuses on intensive R&D to expand its presence in the global bio-industry.

Recent filings

Filing Released Lang Actions
분기보고서 (2020.03)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Komipharm, covering the period from January 1, 2020, to March 31, 2020. It contains comprehensive financial statements, management discussion and analysis, and detailed corporate information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2020
2020-05-14 Korean
투자판단관련주요경영사항(비소세포폐암(NSCLC)에서 이차적으로 뇌전이(BM)가 있는 환자에서의 PAX-1 2상 임상시험계획 승인비소세포폐암(NSCLC)에서 이차적으로 뇌전이(BM)가 있는 환자에서의 PAX-1 2상 임상시험계획 승인)
Legal Proceedings Report Classification · 95% confidence The document is a regulatory filing from the Korea Exchange (KRX) system, specifically a 'Major Management Matter' disclosure regarding the approval of a Phase 2 clinical trial for a drug candidate (PAX-1). Since this is a specific regulatory announcement of a material event (clinical trial approval) and does not fit into categories like financial reports, dividends, or shareholder meetings, it is classified as a general regulatory filing.
2020-05-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used by executives and major shareholders to report changes in their shareholdings in a listed company (Komipharm). This type of filing is classified as 'Director's Dealing' (DIRS) as it details personal share transactions by company insiders.
2020-04-20 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings Classification · 95% confidence The document is a regulatory filing from KOSDAQ-listed company Komipharm regarding a 'Correction Report' (정정신고) for a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결). It details changes to the contract amount and percentage of revenue due to government procurement adjustments. Since this is a specific regulatory disclosure regarding a commercial contract update and does not fit into the other specialized categories like M&A or financial reports, it is classified as a general Regulatory Filing (RNS).
2020-03-31 Korean
사업보고서 (2019.12)
Audit Report / Information Classification · 98% confidence The document is a comprehensive 'Audit Report' (감사보고서) for Komipharm (주식회사 코미팜) for the fiscal year 2019. It includes the independent auditor's report, consolidated financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes. While it contains financial statements, it is explicitly titled as an 'Audit Report' and serves as the formal audit document rather than a full 10-K annual report (which would include management discussion and analysis, business overview, etc.). Therefore, it is classified as an Audit Report. FY 2019
2020-03-30 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 95% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on the Granting of Stock Options). It details the issuance of stock options to specific directors, including the number of shares, exercise price, and valuation methodology (Black-Scholes model). This type of disclosure regarding share-based compensation and capital changes falls under the category of 'Share Issue/Capital Change' (SHA) within the provided classification schema.
2020-03-26 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.